Breakout Stocks
DRTS is part of our breakout stocks list, indicating it is showing strong recent technical strength.
ALPHA TAU MEDICAL LTD (DRTS) Stock Price & Overview
NASDAQ:DRTS • IL0011839383
Current stock price
8.54 USD
+0.2 (+2.4%)
At close:
8.98 USD
+0.44 (+5.15%)
After Hours:
The current stock price of DRTS is 8.54 USD. Today DRTS is up by 2.4%. In the past month the price increased by 23.41%. In the past year, price increased by 229.09%.
DRTS Key Statistics
52-Week Range2.57 - 8.8
Current DRTS stock price positioned within its 52-week range.
1-Month Range6.7 - 8.8
Current DRTS stock price positioned within its 1-month range.
- Market Cap
- 751.605M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.47
- Dividend Yield
- N/A
DRTS Stock Performance
Today
+2.4%
1 Week
+5.56%
1 Month
+23.41%
3 Months
+23.05%
Longer-term
6 Months +105.04%
1 Year +229.09%
2 Years +240.24%
3 Years +115.11%
5 Years N/A
10 Years N/A
DRTS Stock Chart
DRTS Stock Screens
DRTS currently appears in the following ChartMill screener lists.
DRTS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DRTS. When comparing the yearly performance of all stocks, DRTS is one of the better performing stocks in the market, outperforming 97.12% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
DRTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DRTS. DRTS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
DRTS Earnings
Next Earnings DateN/A
Last Earnings DateMar 9, 2026
PeriodQ4 / 2025
EPS Reported-$0.08
Revenue Reported
EPS Surprise 36.49%
Revenue Surprise %
DRTS Forecast & Estimates
10 analysts have analysed DRTS and the average price target is 9.69 USD. This implies a price increase of 13.47% is expected in the next year compared to the current price of 8.54.
Analysts
Analysts84
Price Target9.69 (13.47%)
EPS Next Y-13%
Revenue Next YearN/A
DRTS Financial Highlights
Over the last trailing twelve months DRTS reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS decreased by -4.44% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-42.63M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.35% | ||
| ROE | -55.29% | ||
| Debt/Equity | 0.08 |
Chartmill High Growth Momentum
EPS Q2Q%38.46%
Sales Q2Q%N/A
EPS 1Y (TTM)-4.44%
Revenue 1Y (TTM)N/A
DRTS Ownership
Ownership
Inst Owners2.93%
Shares88.01M
Float59.80M
Ins Owners15.61%
Short Float %1.52%
Short Ratio3.34
DRTS Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | 39.25 | 162.529B | ||
| ABT | ABBOTT LABORATORIES | 14.24 | 157.763B | ||
| SYK | STRYKER CORP | 17.41 | 120.688B | ||
| BSX | BOSTON SCIENTIFIC CORP | 14.31 | 85.619B | ||
| EW | EDWARDS LIFESCIENCES CORP | 24.9 | 48.141B | ||
| IDXX | IDEXX LABORATORIES INC | 38.32 | 44.539B | ||
| BDX | BECTON DICKINSON AND CO | 10.94 | 42.438B | ||
| RMD | RESMED INC | 16.7 | 31.148B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 10.74 | 27.761B | ||
| DXCM | DEXCOM INC | 20.18 | 22.918B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 9.11 | 15.956B | ||
| PEN | PENUMBRA INC | 63.83 | 12.837B | ||
| GMED | GLOBUS MEDICAL INC - A | 20.03 | 12.197B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DRTS
Company Profile
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.
Company Info
IPO: 2022-03-08
ALPHA TAU MEDICAL LTD
Kiryat Hamada 5
JERUSALEM IL
Employees: 121
Phone: 97235774115
ALPHA TAU MEDICAL LTD / DRTS FAQ
What does DRTS do?
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The firm has one subsidiary Healthcare Capital Corp.
What is the current price of DRTS stock?
The current stock price of DRTS is 8.54 USD. The price increased by 2.4% in the last trading session.
Does ALPHA TAU MEDICAL LTD pay dividends?
DRTS does not pay a dividend.
How is the ChartMill rating for ALPHA TAU MEDICAL LTD?
DRTS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ALPHA TAU MEDICAL LTD (DRTS) stock traded?
DRTS stock is listed on the Nasdaq exchange.
Is ALPHA TAU MEDICAL LTD (DRTS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DRTS.